Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > some color behind pancan strategic reevaluation

<< Previous

Bullboard Posts

Next >>

Comment by itntdfon Jan 18, 2024 1:43pm

122 Views

Post# 35834110

RE:some color behind pancan strategic reevaluation

The relationship between PanCAN and GCAR spans many years, as GCAR’s CEO, Dr. Meredith Buxton, played a key role in crafting the original Precision Promise protocol. The alliance between PanCAN and GCAR represents a dynamic synergy, harnessing the strengths of both organizations to accelerate pancreatic cancer research and bring new treatments to patients.

<< Previous

Bullboard Posts

Next >>

How to decrease sector risk by owning hundreds of mineral assets